

CLINDAMYCIN PHOSPHATE- clindamycin phosphate gel

Viona Pharmaceuticals Inc

Clindamycin Phosphate Gel USP, 1%


DESCRIPTION

Clindamycin phosphate gel, USP contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per gram.

Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

The gel contains following inactive ingredient: allantoin, carbopol, methyl paraben, polyethylene glycol, propylene glycol, purified water and sodium hydroxide.

The structural formula is represented below:



The chemical name for clindamycin phosphate is Methyl-7-chloro-6,7,8-trideoxy-6-(1-methyl-*trans*-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-*threo*- α -D-*galacto*-octopyranoside 2-(dihydrogen phosphate).

CLINICAL PHARMACOLOGY

Mechanism of Action

The mechanism of action of clindamycin in treating acne vulgaris is unknown.

Pharmacokinetics

Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0 ng/mL to 3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.

Although clindamycin phosphate is inactive *in vitro*, rapid *in vivo* hydrolysis converts this compound to the antibacterially active clindamycin.

Microbiology

Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.

Antimicrobial Activity

Clindamycin is active *in vitro* against most isolates of *Propionibacterium acnes*; however, the clinical significance is unknown.

Resistance

Resistance to clindamycin is most often caused by modification of specific bases of the 23S ribosomal RNA. Cross-resistance between clindamycin and lincomycin is complete. Because the binding sites for these antibacterial drugs overlap, cross resistance is sometimes observed among lincosamides, macrolides and streptogramin B. Macrolide-inducible resistance to clindamycin occurs in some isolates of macrolide-resistant bacteria.

INDICATIONS AND USAGE

Clindamycin phosphate gel is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see **CONTRAINDICATIONS, WARNINGS** and **ADVERSE REACTIONS**).

CONTRAINDICATIONS

Clindamycin phosphate gel is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis or a history of antibiotic-associated colitis.

WARNINGS

Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis. Stool culture for *Clostridium difficile* and stool assay for *C. difficile* toxin may be helpful diagnostically.

When significant diarrhea occurs, the drug should be discontinued. Large

bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.

Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by *Clostridium difficile*. The usual adult dosage is 500 milligrams to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 days to 10 days. Cholestyramine or colestipol resins bind vancomycin *in vitro*. If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

Diarrhea, colitis and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.

PRECAUTIONS

General

Clindamycin phosphate gel should be prescribed with caution in atopic individuals.

Drug Interactions

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Pregnancy

Teratogenic effects

In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital abnormalities. There are no adequate studies in pregnant women during the first trimester of pregnancy. Clindamycin should be used during the first trimester of pregnancy only if clearly needed.

Nursing Mothers

It is not known whether clindamycin is excreted in breast milk following use of clindamycin phosphate gel. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition.

Clinical Considerations

If used during lactation and clindamycin phosphate gel is applied to the chest, care should be taken to avoid accidental ingestion by the infant.

Pediatric Use

Safety and effectiveness in pediatric patients under the age of 12 have not been established.

Geriatric Use

Clinical studies for clindamycin phosphate gel did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

ADVERSE REACTIONS

In 18 clinical studies of various formulations of clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

| Treatment Emergent Adverse Event | Number of Patients Reporting Events | | |
|---|--|-------------------------|----------------------------|
| | Solution n=553(%) | Gel n=148(%) | Lotion n=160(%) |
| Burning | 62 (11) | 15 (10) | 17 (11) |
| Itching | 36 (7) | 15 (10) | 17 (11) |
| Burning/Itching | 60 (11) | # (-) | # (-) |
| Dryness | 105 (19) | 34 (23) | 29 (18) |
| Erythema | 86 (16) | 10 (7) | 22 (14) |
| Oiliness/Oily Skin | 8 (1) | 26 (18) | 12* (10) |
| Peeling | 61 (11) | # (-) | 11 (7) |

not recorded

* of 126 subjects

Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.

Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see **WARNINGS**).

Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin.

OVERDOSAGE

Topically applied clindamycin phosphate gel can be absorbed in sufficient amounts to produce systemic effects (see **WARNINGS**).

DOSAGE AND ADMINISTRATION

Apply a thin film of clindamycin phosphate gel twice daily to affected area.

Keep containers tightly closed.

HOW SUPPLIED

Clindamycin phosphate gel USP, 1% containing clindamycin phosphate equivalent to 10 mg clindamycin per gram are a transparent gel free from lumps and foreign matter without any separation and is supplied as follows:

NDC 72578-118-01 in tube of 30 g

NDC 72578-118-02 in tube of 60 g

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

Protect from freezing.

Call your doctor for medical advice about side effects. You may report side effects to Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088.

For more information, go to Viona Pharmaceuticals Inc. at 1-888-304-5011.

Manufactured by:

Zydus Lifesciences Ltd.

Ahmedabad, India

Distributed by:

Viona Pharmaceuticals Inc.

Cranford, NJ 07016

Rev.: 05/22

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Clindamycin Phosphate Gel USP, 1%

30 g

NDC 72578-118-01

Rx only

Zydus

NDC 72578-118-01

Clindamycin Phosphate Gel, USP

1%

For topical use only



30 g
Rx only

For external use only. Avoid contact with eyes.

DOSAGE AND USE: See accompanying prescribing information.

Each gram contains clindamycin phosphate, USP equivalent to 10 mg (1%) of clindamycin. Inactive Ingredient allantoin, carbopol, methyl paraben, polyethylene glycol, propylene glycol, purified water and sodium hydroxide.

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F)

[See USP Controlled Room Temperature]. Protect from freezing.

Keep this and all drugs out of the reach of children.

See crimp of tube for Expiration Date and Lot Number.


Manufactured by:
Zydus Lifesciences Ltd.
Changodar, Ahmedabad, India

Distributed by:
Viona Pharmaceuticals Inc.
Cranford, NJ 07016



Rev: 05/22





CLINDAMYCIN PHOSPHATE

clindamycin phosphate gel

Product Information

| | | | |
|--------------------------------|-------------------------|---------------------------|---------------|
| Product Type | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:72578-118 |
| Route of Administration | TOPICAL | | |

Active Ingredient/Active Moiety

| Ingredient Name | Basis of Strength | Strength |
|---|-----------------------|--------------|
| CLINDAMYCIN PHOSPHATE (UNII: EH6D7113I8) (CLINDAMYCIN - UNII:3U02EL437C) | CLINDAMYCIN PHOSPHATE | 10 mg in 1 g |

Inactive Ingredients

| Ingredient Name | Strength |
|--|----------|
| ALLANTOIN (UNII: 344S277G0Z) | |
| CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: HHT01Z NK31) | |
| METHYL PARABEN (UNII: A2I8C7HI9T) | |
| POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ) | |
| PROPYLENE GLYCOL (UNII: 6DC9Q167V3) | |

SODIUM HYDROXIDE (UNII: 55X04QC32I)

WATER (UNII: 059QF0KO0R)

Packaging

| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
|---|------------------|---|----------------------|--------------------|
| 1 | NDC:72578-118-01 | 1 in 1 CARTON | 09/20/2023 | |
| 1 | | 30 g in 1 TUBE; Type 0: Not a Combination Product | | |
| 2 | NDC:72578-118-02 | 1 in 1 CARTON | 09/20/2023 | |
| 2 | | 60 g in 1 TUBE; Type 0: Not a Combination Product | | |

Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------|--|----------------------|--------------------|
| ANDA | ANDA216587 | 09/20/2023 | |

Labeler - Viona Pharmaceuticals Inc (081468959)

Registrant - Zydus Lifesciences Limited (650199482)

Establishment

| Name | Address | ID/FEI | Business Operations |
|----------------------------|---------|-----------|--|
| Zydus Lifesciences Limited | | 650650802 | ANALYSIS(72578-118) , MANUFACTURE(72578-118) |

Revised: 12/2024

Viona Pharmaceuticals Inc